The latest version price and authenticity of brigatinib/brigatinib in India

Brigatinib/Brigatinib (Brigatinib) is an ALK inhibitor developed by Takeda Pharmaceuticals of the United States. It is mainly used for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC). With the widespread use of targeted drugs in clinical practice, patients are particularly concerned about drug prices, version differences, and identification of authenticity. It should be noted that there are currently no generic or original drugs of brigatinib produced in India. If the so-called "Indian version of brigatinib" appears on the market, it is likely to be a fake and shoddy product, which poses a greater risk. Patients must remain vigilant when choosing drug channels.

In overseas markets, there are indeed some cost-effective generic options for brigatinib, such as the version from Laos pharmaceutical companies. These generic drugs are consistent with the original drugs in terms of drug ingredients and dosage design to meet clinical treatment needs. Taking a 90mg*30 tablet generic drug as an example, the price is about 500 yuan, but due to exchange rate fluctuations and channel differences, the actual price may be different. In comparison, the market price of original drugs is much higher, which is often beyond the affordability of most patients.

In terms of identifying authenticity, we must first check whether the drug packaging is regular, including whether the manufacturer information, batch number, expiration date, etc. are complete. Secondly, the appearance and coding of the tablets can be compared with the official information. In addition, formal channels usually provide customs documents or registration information from the drug regulatory department, while low-priced drugs from unknown sources may pose safety risks. Although overseas generic drugs are cheaper, they still need to be purchased through qualified channels to avoid delays in treatment due to the purchase of counterfeit drugs.

With the deepening of international exchanges, the ways for patients to obtain generic drugs have become more diversified. As an innovativeALK inhibitor, the efficacy of brigatinib has been recognized internationally, but the safety and standardized use of treatment courses require more reliable drug guarantees.

Reference materials:https://www.alunbrig.com/